Boston Trust Walden Corp Sells 12,968 Shares of Chemed Corporation $CHE

Boston Trust Walden Corp cut its position in shares of Chemed Corporation (NYSE:CHE) by 5.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 234,466 shares of the company’s stock after selling 12,968 shares during the quarter. Chemed comprises 0.8% of Boston Trust Walden Corp’s investment portfolio, making the stock its 26th biggest holding. Boston Trust Walden Corp owned approximately 1.61% of Chemed worth $104,980,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the business. Cim LLC boosted its stake in Chemed by 1.0% in the 1st quarter. Cim LLC now owns 2,029 shares of the company’s stock worth $1,248,000 after purchasing an additional 21 shares in the last quarter. Atria Investments Inc grew its position in Chemed by 0.6% in the 2nd quarter. Atria Investments Inc now owns 4,259 shares of the company’s stock worth $2,074,000 after purchasing an additional 25 shares during the period. Cetera Investment Advisers grew its holdings in shares of Chemed by 1.5% in the second quarter. Cetera Investment Advisers now owns 1,740 shares of the company’s stock worth $847,000 after acquiring an additional 25 shares during the period. HM Payson & Co. grew its stake in shares of Chemed by 35.5% during the 3rd quarter. HM Payson & Co. now owns 103 shares of the company’s stock valued at $46,000 after purchasing an additional 27 shares during the period. Finally, First Horizon Advisors Inc. raised its holdings in Chemed by 16.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 202 shares of the company’s stock worth $99,000 after purchasing an additional 29 shares during the period. Institutional investors own 95.85% of the company’s stock.

Wall Street Analyst Weigh In

CHE has been the topic of several analyst reports. Bank of America lowered their price target on shares of Chemed from $610.00 to $595.00 and set a “buy” rating on the stock in a report on Wednesday, September 10th. Zacks Research raised shares of Chemed from a “strong sell” rating to a “hold” rating in a report on Thursday, October 30th. Weiss Ratings reissued a “hold (c-)” rating on shares of Chemed in a report on Wednesday, October 8th. Royal Bank Of Canada cut their price target on Chemed from $589.00 to $572.00 and set an “outperform” rating for the company in a report on Monday, November 10th. Finally, Jefferies Financial Group raised Chemed from a “hold” rating to a “buy” rating and upped their price objective for the stock from $490.00 to $550.00 in a report on Tuesday, September 2nd. Four analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Chemed currently has a consensus rating of “Moderate Buy” and a consensus target price of $574.25.

Insider Buying and Selling

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $437.55, for a total value of $875,100.00. Following the sale, the chief executive officer owned 94,197 shares of the company’s stock, valued at $41,215,897.35. The trade was a 2.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.29% of the stock is owned by corporate insiders.

Chemed Stock Performance

Shares of CHE stock opened at $432.58 on Monday. Chemed Corporation has a fifty-two week low of $408.42 and a fifty-two week high of $623.60. The stock’s 50-day simple moving average is $435.54 and its 200-day simple moving average is $454.06. The firm has a market capitalization of $6.13 billion, a price-to-earnings ratio of 22.88, a PEG ratio of 2.41 and a beta of 0.46.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $5.27 earnings per share for the quarter, missing the consensus estimate of $5.39 by ($0.12). The business had revenue of $624.90 million during the quarter, compared to analyst estimates of $626.04 million. Chemed had a return on equity of 25.89% and a net margin of 11.02%.Chemed’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same quarter last year, the company posted $5.64 EPS. Chemed has set its FY 2025 guidance at 22.000-22.300 EPS. As a group, equities analysts forecast that Chemed Corporation will post 21.43 earnings per share for the current year.

Chemed Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Monday, November 17th were issued a $0.60 dividend. This represents a $2.40 annualized dividend and a yield of 0.6%. The ex-dividend date was Monday, November 17th. Chemed’s payout ratio is presently 12.69%.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.